Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

US11673894B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Xiaozhao Wang · Readington, US
• Pei Gan · Claymont, US
• Taisheng Huang · Wilmington, US
• Chao Qi · Newark, US
• Ding-Quan Qian · Newark, US
• Liangxing Wu · Wilmington, US
• Wenqing Yao · Kennett Square, US
• Zhiyong Yu · Zhejiang, CN
• Fenglei Zhang · Berwyn, US
• Le Zhao · Wilmington, US
• Chunhong He · Boothwyn, US

Key dates

• Filing date: Oct 22, 2020
• Grant date: Jun 13, 2023
• Expiry date: Oct 22, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.